Pharma channel feed

Flori­da judge dis­miss­es No­vo Nordisk law­suit over com­pound­ed semaglu­tide, but com­pa­ny plans to file again

Last year
Law

Set­ting up a show­down with Boehringer, Pfiz­er scores in­ter­change­abil­i­ty tag for its Hu­mi­ra biosim­i­lar

Last year
FDA+

Astel­las pro­pos­es ‘More Not Flash­es' in first brand­ed ad for Veozah menopause treat­ment

Last year
Marketing

Cal­i­for­nia gov­er­nor ve­toes bill to cap in­sulin prices at $35 per month

Last year
FDA+

Bio­con’s in­sulin biosim­i­lar re­ject­ed yet again by FDA af­ter man­u­fac­tur­ing de­fi­cien­cies

Last year
Manufacturing

Hamas strikes could im­pact some bio­phar­ma op­er­a­tions in Is­rael

Last year
R&D

Scoop: No­var­tis ax­es mid-stage de­pres­sion tri­al of ke­t­a­mine-like in­jec­tion

Last year
R&D

FDA re­jects Al­ny­lam’s On­pat­tro la­bel ex­pan­sion af­ter ad­comm vot­ed in fa­vor

Last year
R&D
FDA+

Gal­der­ma re­news an­nu­al breast can­cer aware­ness cam­paign with per­son­al sto­ries of sur­vivors

Last year
Marketing

CBO analy­sis calls for more re­search in­to sav­ings po­ten­tial for obe­si­ty treat­ments

Last year
FDA+

Pfiz­er and Ab­b­Vie oral mi­graine drugs earn top spots with physi­cians, sur­vey finds

Last year
Marketing

Dis­counts for weight loss drugs are es­ti­mat­ed at more than half, fu­el­ing ques­tions about price, PBMs and cov­er­age

Last year

Pfiz­er and BioN­Tech re­solve mR­NA patent law­suit filed by Pro­mo­some

Last year
Law

Ar­cutis wins la­bel ex­pan­sion for younger use of pso­ri­a­sis cream Zo­ryve

Last year
FDA+

Mi­rati is once again the cen­ter of buy­out ru­mors, and a ri­val's ad­comm pro­vides a boost

Last year

Am­gen clos­es $28B Hori­zon ac­qui­si­tion a month af­ter FTC bat­tle end­ed

Last year
Deals

Apel­lis’ Syfovre on the come­back trail from vas­culi­tis wor­ries af­ter $74M in ini­tial Q3 sales

Last year

HHS an­nounces move to com­mer­cial dis­tri­b­u­tion for Mer­ck­'s an­tivi­ral Lagevrio

Last year

Rea­gan-Udall Foun­da­tion lays out meth­ods for FDA to com­bat mis­in­for­ma­tion

Last year
FDA+

Newest FDA-ap­proved opi­oid use dis­or­der drug en­ters the mar­ket with flex­i­ble dos­ing

Last year
Marketing

Im­pel con­sid­ers strate­gic al­ter­na­tives, takes out $2.5M loan to con­tin­ue op­er­at­ing

Last year
People

Patent ap­peal board takes up Ozem­pic chal­lenge

Last year

Slew of phar­ma in­dus­try play­ers form coali­tion to push back against an­titrust re­form

Last year
FDA+

San­doz shares dip on first day of Swiss list­ing af­ter No­var­tis spin­off

Last year
First page Previous page 9899100101102103104 Next page Last page
A service from the Financial Times